BMRN
Income statement / Annual
Last year (2023), BioMarin Pharmaceutical Inc.'s total revenue was $2.42 B,
an increase of 15.42% from the previous year.
In 2023, BioMarin Pharmaceutical Inc.'s net income was $167.65 M.
See BioMarin Pharmaceutical Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$2.42 B
|
$2.10 B
|
$1.85 B
|
$1.86 B
|
$1.70 B
|
$1.49 B
|
$1.31 B
|
$1.12 B
|
$889.90 M
|
$751.04 M
|
| Cost of Revenue |
$514.85 M |
$483.67 M |
$470.52 M |
$524.27 M |
$359.47 M |
$315.26 M |
$241.79 M |
$209.62 M |
$152.01 M |
$129.76 M |
| Gross Profit |
$1.90 B |
$1.61 B |
$1.38 B |
$1.34 B |
$1.34 B |
$1.18 B |
$1.07 B |
$907.23 M |
$737.89 M |
$621.28 M |
| Gross Profit Ratio |
0.79 |
0.77 |
0.75 |
0.72 |
0.79 |
0.79 |
0.82 |
0.81 |
0.83 |
0.83 |
| Research and Development
Expenses |
$746.77 M
|
$649.61 M
|
$628.79 M
|
$628.12 M
|
$715.01 M
|
$696.33 M
|
$610.75 M
|
$661.91 M
|
$634.81 M
|
$461.54 M
|
| General & Administrative
Expenses |
$448.90 M
|
$403.71 M
|
$354.30 M
|
$334.30 M
|
$0.00
|
$604.35 M
|
$554.34 M
|
$476.59 M
|
$402.27 M
|
$302.16 M
|
| Selling & Marketing
Expenses |
$488.40 M
|
$450.30 M
|
$405.10 M
|
$403.40 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$937.30 M
|
$854.01 M
|
$759.38 M
|
$737.67 M
|
$680.92 M
|
$604.35 M
|
$554.34 M
|
$476.59 M
|
$402.27 M
|
$302.16 M
|
| Other Expenses |
$0.00 |
$67.19 M |
$69.93 M |
$66.66 M |
$74.11 M |
$2.21 M |
$7.97 M |
$4.93 M |
-$9.30 M |
$279,000.00 |
| Operating Expenses |
$1.75 B |
$1.57 B |
$1.46 B |
$1.43 B |
$1.47 B |
$1.35 B |
$1.21 B |
$1.11 B |
$1.02 B |
$781.67 M |
| Cost And Expenses |
$2.26 B |
$2.05 B |
$1.93 B |
$1.96 B |
$1.83 B |
$1.66 B |
$1.45 B |
$1.32 B |
$1.17 B |
$911.43 M |
| Interest Income |
$58.34 M |
$18.03 M |
$10.48 M |
$16.61 M |
$22.75 M |
$22.83 M |
$14.85 M |
$7.49 M |
$4.50 M |
$5.94 M |
| Interest Expense |
$17.34 M |
$15.97 M |
$15.34 M |
$29.31 M |
$23.46 M |
$43.66 M |
$42.71 M |
$39.50 M |
$38.24 M |
$36.64 M |
| Depreciation &
Amortization |
$104.39 M
|
$101.97 M
|
$108.04 M
|
$105.88 M
|
$105.30 M
|
$95.50 M
|
$87.92 M
|
$86.03 M
|
-$17.69 M
|
$17.97 M
|
| EBITDA |
$310.28 M
|
$267.52 M
|
$48.03 M
|
-$5.85 M
|
$33.95 M
|
-$3.54 M
|
$94.76 M
|
-$705.53 M
|
-$110.70 M
|
-$49.96 M
|
| EBITDA Ratio |
0.13 |
0.08 |
0.03 |
-0 |
-0.01 |
-0.07 |
-0.05 |
-0.17 |
-0.32 |
-0.18 |
| Operating Income Ratio
|
0.08
|
0.03
|
-0.03
|
-0.05
|
-0.07
|
-0.08
|
-0.01
|
-0.72
|
-0.12
|
-0.12
|
| Total Other
Income/Expenses Net |
-$5.88 M
|
$14,000.00
|
-$15.34 M
|
-$5.56 M
|
$5.65 M
|
-$19.18 M
|
-$35.86 M
|
-$27.62 M
|
-$44.02 M
|
-$31.98 M
|
| Income Before Tax |
$188.56 M |
$149.58 M |
-$75.35 M |
-$42.32 M |
-$94.81 M |
-$142.71 M |
-$35.88 M |
-$831.05 M |
-$154.72 M |
-$124.87 M |
| Income Before Tax Ratio
|
0.08
|
0.07
|
-0.04
|
-0.02
|
-0.06
|
-0.1
|
-0.03
|
-0.74
|
-0.17
|
-0.17
|
| Income Tax Expense |
$20.92 M |
$8.02 M |
-$11.27 M |
-$901.42 M |
-$70.96 M |
-$65.49 M |
$81.17 M |
-$200.84 M |
$17.08 M |
$9.10 M |
| Net Income |
$167.65 M |
$141.56 M |
-$64.08 M |
$854.03 M |
-$23.85 M |
-$77.21 M |
-$117.04 M |
-$630.21 M |
-$171.80 M |
-$133.97 M |
| Net Income Ratio |
0.07 |
0.07 |
-0.03 |
0.46 |
-0.01 |
-0.05 |
-0.09 |
-0.56 |
-0.19 |
-0.18 |
| EPS |
0.89 |
0.76 |
-0.35 |
4.75 |
-0.13 |
-0.44 |
-0.67 |
-3.8 |
-1.07 |
-0.92 |
| EPS Diluted |
0.87 |
0.75 |
-0.35 |
4.53 |
-0.13 |
-0.44 |
-0.67 |
-3.79 |
-1.07 |
-0.92 |
| Weighted Average Shares
Out |
$187.83 M
|
$185.27 M
|
$182.85 M
|
$180.80 M
|
$179.04 M
|
$177.06 M
|
$174.43 M
|
$165.99 M
|
$160.03 M
|
$145.62 M
|
| Weighted Average Shares
Out Diluted |
$191.60 M
|
$188.96 M
|
$182.85 M
|
$191.68 M
|
$179.04 M
|
$177.27 M
|
$174.43 M
|
$166.22 M
|
$160.03 M
|
$146.35 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
